[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-rhinosinusitis-with-nasal-polyps-crswnp\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-rhinosinusitis-with-nasal-polyps-crswnp":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,40,67,90,127,150,177,201,222,245,266,296,320,348,369,399],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100542140","phase-3-a-study-of-lebrikizumab-ly3650150-in-participants-with-chronic-rhinosinusitis-and-nasal-polyps-treated-with-intranasal-corticosteroids-contrast-np-100542140",false,"NCT06338995","A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab\u002FLY3650150 in Participants With Chronic Rhinosinusitis With Nasal Polyps on Background Intranasal Corticosteroids","Inclusion Criteria:\n\n* Physician-diagnosed chronic rhinosinusitis (CRS) with bilateral nasal polyps (NP).\n* Prior treatment with systemic corticosteroids (SCS) within the last 2 years (or a medical contraindication or intolerance to SCS), prior surgery for NP, or both.\n* Endoscopic bilateral NPS score of at least 5 out of 8, with a minimum score of 2 in each nasal cavity performed at screening and baseline.\n* Ongoing symptoms for at least 8 weeks prior to study entry (screening), including:\n\n  1. Nasal congestion with moderate or severe symptom severity (score 2 or 3) at screening and a weekly average severity score of at least 1 (range 0 to 3) at randomization, and\n  2. At least one other symptom, such as partial loss of smell (hyposmia), total loss of smell (anosmia), or anterior or posterior rhinorrhea.\n* Have concomitant asthma must be stable in the 3 months prior to screening using permitted regular asthma treatment.\n* Adolescent participants ≥12 to \\\u003C18 years of age and weighing ≥40 kg at time of Visit 1.\n\nExclusion Criteria:\n\n* Have received a dose of lebrikizumab.\n* Have received treatment with any rescue medication and\u002For have the need for surgery for NP during screening and\u002For run-in period.\n* Allergen immunotherapy (subcutaneous immunotherapy \\[SCIT\\]\u002Fsublingual immunotherapy \\[SLIT\\]) initiated within 6 months prior to screening, that is not on a stable dose (3 months prior to screening).\n* Has received a biologic treatment approved for use in CRSwNP, asthma, or AD, even if administered to treat a different condition, within 4 months or 5 half-lives, whichever is longer, prior to screening.\n* Have received treatment with any biologic or systemic immunosuppressants for inflammatory disease or autoimmune disease prior to the baseline visit:\n\n  1. B cell-depleting biologics, including rituximab, within 6 months.\n  2. other biologics within 5 half-lives (if known) or 8 weeks, whichever is longer.\n  3. Systemic immunosuppressants within 4 weeks prior to baseline.\n* Have had any sinus intranasal surgery (including nasal polypectomy) within 6 months prior to screening\n* Have had prior sino-nasal surgery or sinus surgery changing lateral wall structure of the nose making it difficult to assess endoscopic NPS\n* Have a presence of any of the following conditions that may impact the assessment of endpoints at screening or baseline:\n\n  1. Nasal septal deviation occluding at least one nostril.\n  2. Antrochoanal polyps.\n  3. Acute sinusitis, acute nasal infection, or acute upper respiratory infection.\n  4. Ongoing rhinitis medicamentosa.\n  5. Presence of another diagnosis associated with NP (ie, eosinophilic granulomatosis with polyangiitis, granulomatosis with polyangiitis, Young's syndrome, primary ciliary dyskinesia, cystic fibrosis). Note: for adolescents, documentation for ruling out cystic fibrosis and primary ciliary dyskinesia is required.\n  6. A nasal cavity tumor (malignant or benign).\n  7. Evidence of fungal rhinosinusitis.\n* Have anosmia from COVID or any reason other than CRSwNP.\n* Participants with forced expiratory volume in 1 second (FEV1) 50% or less (of predicted normal) at screening.\n* Female participant who is pregnant, breastfeeding, or is planning to become pregnant, or to breastfeed during the study.","ALL","12 Years",{"count":19,"type":20},510,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.",[26],"Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)","RECRUITING","2026-06-17",{"date":30,"type":31},"2026-06-18","ACTUAL",{"date":33,"type":31},"2024-04-29",{"date":35,"type":20},"2028-03",{"name":37,"class":38},"Eli Lilly and Company","INDUSTRY",194,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100643734","prospective-non-interventional-single-arm-study-with-tezepelumab-to-investigate-the-change-in-clinical-and-patient-reported-outcomes-in-patients-with-crswnp-in-real-world-petrichor-100643734","NCT07633158","Prospective, Non-interventional Single-arm Study With Tezepelumab to Investigate the Change in Clinical and Patient-reported Outcomes in Patients With CRSwNP in Real-world (PETRICHOR)","PETRICHOR","Inclusion Criteria:\n\n* \\- Participant must be 18 years of age or older, at the time of signing the informed consent.\n* \\- Confirmed diagnosis of CRSwNP for at least 12 months prior to routine care visit 1.\n* \\- Stable standard of care (SoC) treatment with Intranasal corticosteroids (INCS) for CRSwNP for at least 30 days prior to routine care visit 1.\n* \\- Physician decision that participant is eligible for treatment with Tezepelumab according to locally approved CRSwNP label.\n* Participants must be able and willing to read and comprehend written instructions, to collect Patient-reported outcome (PROs) and medication intake via app or alternative mode (paper) and to sign the informed consent document. Use of the mobile app is optional; participants without smartphones will not be excluded. Mode of data capture will be recorded and adjusted for in analyses where relevant.\n* \\- Participants who will be enrolled after index date need to have at least one measurement for SNOT-22 prior (within a maximum of 4 weeks) to index date.\n* \\- -\n\nExclusion Criteria:\n\n* \\- Participants who participate in an observational study that might influence the assessment of the current study (participants can be part of the German National Registry for Chronic rhinosinusitis (GENRE-CRS)); or participate in an interventional clinical trial in the last 3 months.\n* \\- Concurrent biologic therapy for CRSwNP or Asthma except where the last dose was administered ≥ 30 days. Stable allergen immunotherapy (defined as a stable dose and regimen at the time of enrolment) is allowed.\n* \\- Endoscopic NP surgery within 6 months prior to index date.\n* \\- Condition (acute or chronic) that, in the investigator's opinion, would limit the participant's ability to complete questionnaires or participate in this study.\n* \\- History of documented anaphylactic reactions\u002Fhypersensitivity\u002Fserious allergic reactions (immune complex disease) following any biologic therapy.\n* \\- Known hypersensitivity to Tezepelumab or any of its excipients.\n* \\- Pregnancy, planned pregnancy or lactation period.\n* \\- -","18 Years","130 Years",{"count":50,"type":20},200,"OBSERVATIONAL","PETRICHOR is a prospective, non-interventional, single-arm, multi-centre study in Germany evaluating real-world clinical and patient-reported outcomes in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP), whose disease is inadequately controlled with systemic corticosteroids (SCS) and\u002For surgery. Eligible participants are newly initiated on subcutaneous tezepelumab in routine clinical practice, in accordance with the European Summary of Product Characteristics (SmPC). Treatment decisions are made jointly by patients and their physicians, independent of study enrollment. No additional diagnostic or monitoring procedures are applied; data are collected using epidemiological methods at baseline and during routine clinical visits for up to 104 weeks.",[26],[55,56],"Tezepelumab","Chronic rhinosinusitis with nasal polyps (CRSwNP)","NOT_YET_RECRUITING","2026-06-03",{"date":60,"type":31},"2026-06-08",{"date":62,"type":20},"2026-06-30",{"date":64,"type":20},"2029-12-31",{"name":66,"class":38},"AstraZeneca",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},"100623671","real-world-evaluation-of-tezepelumab-for-chronic-rhinosinusitis-with-nasal-polyps-in-russia-100623671","NCT07399665","ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in Russia","Open-label Single-arm, Non-interventional, Multi-centre Study for Evaluation of Clinical and Patient Reported Outcomes in Adult Patients With CRSwNP on Tezepelumab","ARES","Inclusion Criteria:\n\n1. Male or female participants aged 18 years or older at the time of signing the ICF.\n2. Diagnosis of CRSwNP established for at least 52 weeks prior to tezepelumab initiation.\n3. Availability of participants' medical records for at least 52 weeks prior to tezepelumab initiation, including history of sCS use \u002F nasal polyps surgery (or information about contraindications \u002F intolerance to).\n4. Prescribed and initiated treatment with tezepelumab according to SmPC and local market reimbursement criteria. A period between treatment initiation and enrolment should be no more than 4 weeks.\n5. The severity of CRSwNP consistent with need for surgery as defined by total NPS ≥ 5 (at least 2 for each nostril) at the enrollment.\n6. Nasal Blockage score as part of SNOT-22 (NBS-SNOT-22) ≥ 3 at the enrollment.\n7. SNOT-22 total score ≥ 30 at enrollment or up to 12 weeks before enrollment.\n8. Currently receive care from specialist physicians (e.g., otolaryngologist) at the Investigator's or sub-Investigator's site.\n9. Provision of signed and dated written informed consent.\n10. Participants are able to read, understand and complete the questionnaires required by the protocol.\n\nExclusion Criteria:\n\n1. Any contraindication to tezepelumab as per the approved product SmPC in Russia or in the opinion of the Investigator.\n2. Administration of concurrent biologic drug for CRSwNP \u002F asthma since the index date, except for stable allergen immunotherapy (defined as a stable dose and regimen at the time of enrolment). Enrolment of patients who were switched from other biologic(s) to tezepelumab is allowed, and an acceptable timeframe since the last prior biologic drug is ≥ 60 days. The number of participants with prior biologic treatment (switching to tezepelumab) should be targeted at 20% or less.\n3. Participation in an observational study that might, in the Investigator's opinion, influence the assessment for the current study, or participation in an interventional clinical trial in the last 3 months.\n4. Pregnancy or lactation period.",{"count":76,"type":20},110,"ARES is a multi-centre, retrospective-prospective, non-comparative and non-interventional (observational) cohort study involving primary and secondary data collection within real-world settings of participants who have initiated tezepelumab (no more than 4 weeks before inclusion) for treatment of CRSwNP (with or without comorbid asthma).",[26,79],"Asthma",[55,81],"CRSwNP","2026-06-02",{"date":58,"type":31},{"date":85,"type":31},"2025-12-25",{"date":87,"type":20},"2028-03-31",{"name":66,"class":38},11,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":100,"briefSummary":102,"conditions":103,"keywords":104,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":121,"leadSponsor":123,"locationsCount":126},"100637410","preoperative-stapokibart-for-endoscopic-sinus-surgery-in-chronic-rhinosinusitis-with-nasal-polyps-100637410","NCT07616609","Preoperative Stapokibart for Endoscopic Sinus Surgery in Chronic Rhinosinusitis With Nasal Polyps","A Randomized, Placebo-Controlled, Double-Blinded Trial of Preoperative Stapokibart With Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps","Inclusion Criteria:\n\n* Possess the ability to understand the nature of the study and voluntarily sign an informed consent form (ICF);\n* Age between 18 and 75 years old, with no limitation on gender;\n* Bilateral CRSwNP meeting the diagnostic criteria of the Chinese Guidelines for the Diagnosis and Treatment of Chronic Sinusitis (2024);\n* Persistent presence of the following symptoms for ≥12 weeks prior to the screening\u002Fintroduction period:\n* Nasal congestion;\n* Any other symptom such as decreased\u002Floss of smell or rhinorrhea;\n* At the screening\u002Fintroduction period and baseline, total NPS ≥ 4 points and NPS ≥ 2 points in each nasal cavity;\n* At the screening\u002Fintroduction period and baseline, the subject reports moderate to severe nasal congestion or decreased smell (NCS or LoS score of 2 or 3 points);\n* During the screening\u002Fintroduction period, the Lund-Mackay score on sinus CT is ≥12 points bilaterally and ≥6 points unilaterally;\n* Must meet any of the following criteria for type 2 inflammation: Eosinophil count \\>55\u002Fhigh-power field or eosinophil percentage \\>27% in nasal polyp tissue during the induction period; eosinophil percentage ≥3.75% in peripheral blood in patients with asthma; eosinophil percentage ≥6.9% in patients without asthma;\n* If the subject has asthma, the condition must be stable as assessed by the investigator or specialist. For subjects treated with a stable dose of inhaled corticosteroids for at least 4 weeks before screening, the treatment may be continued during the study period, and the daily dose of inhaled corticosteroids must be ≤1000 μg fluticasone propionate or an equivalent dose of other inhaled corticosteroids.\n\nExclusion Criteria:\n\n* Previous ESS surgery including but not limited to septoplasty, turbinate reduction, nasal polyp removal, and sinus surgery;\n* Contraindications to general anesthesia;\n* Contraindications to stapokibart therapy;\n* Previous use of any anti-IL-4Rα biologic;\n* The patient has conditions or comorbidities that may prevent them from being evaluated for the primary efficacy endpoint, such as acute rhinitis, nasal infection or upper respiratory tract infection within 2 weeks prior to the screening period, acute asthma exacerbation within 4 weeks, current drug-induced rhinitis, allergic fungal sinusitis (AFRS), benign or malignant nasal tumors;\n* Important clinical comorbidities that may interfere with clinical efficacy results, including but not limited to active upper or lower respiratory tract infection, cystic fibrosis, eosinophilic granuloma with polyangiitis (Churg-Strauss syndrome), granuloma with polyangiitis (Wegener's granulomatosis), Young's syndrome, etc.;\n* Accompanied by other poorly controlled serious diseases or recurrent chronic diseases such as (but not limited to) active infection, cardiovascular disease, tuberculosis or other pathogen infection, diabetes, autoimmune diseases, HIV, hepatitis B, hepatitis C or parasitic diseases, malignant tumors, etc.;\n* Subjects with severe liver or kidney dysfunction, such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels \\> 2 times the upper limit of normal, and serum creatinine \\> the upper limit of normal;\n* Subjects with known or suspected immunosuppression, including those with a history of invasive opportunistic infections (such as tuberculosis, histoplasmosis, listeriosis, coccidioidomycosis, pulmonary cystitis, aspergillosis), even if the infection has subsided;\n* Women who are pregnant or planning to become pregnant during the study period, or who are breastfeeding;\n* Subjects of childbearing age who do not wish to use medically approved effective contraception;\n* Subjects with a history of alcohol or drug abuse;\n* Subjects deemed by the investigator to have other medical or non-medical conditions that make them unsuitable for participation in this study.","75 Years",{"count":99,"type":20},48,[101],"NA","This is a single-center, randomized, double-blinded, placebo-controlled clinical trial in adults with moderate-to-severe chronic rhinosinusitis with nasal polyps (CRSwNP) who have no previous nasal surgery.\n\nThe purpose of this study is to evaluate the effectiveness and safety of using stapokibart for 4 weeks before endoscopic sinus surgery (ESS), compared with placebo before ESS.\n\nThe main questions this study aims to answer are:\n\n* Does preoperative stapokibart combined with endoscopic sinus surgery achieve better efficacy and comparable safety compared with surgery alone?\n* What influences four-week preoperative stapokibart administration has on pharmacodynamic data and intraoperative surgical parameters？\n* Is there a correlation between the efficacy of four-week stapokibart therapy and postoperative recurrence tendency after endoscopic sinus surgery?\n\nResearchers will randomly assign participants to receive either stapokibart or a placebo (an inactive substance that looks like the study drug) for 4 weeks before surgery. All participants will have the same standard endoscopic sinus surgery and will be followed for 48 weeks to check polyp status, symptoms, quality of life, and adverse events.\n\nThis study will provide evidence about whether short-term preoperative stapokibart improves surgical and long-term outcomes for adults with CRSwNP undergoing ESS.",[26],[105,106,107,108,109,110,111,112,113,114,115,116],"chronic rhinosinusitis with nasal polyps","nasal polyps","stapokibart","endoscopic sinus surgery","type 2 inflammation","randomized controlled trial","surgical outcome","preoperative biologic therapy","disease recurrence","double-blinded method","clinical safety","treatment efficacy","2026-05-27",{"date":119,"type":31},"2026-06-01",{"date":119,"type":20},{"date":122,"type":20},"2028-12-31",{"name":124,"class":125},"Beijing Tongren Hospital","OTHER",1,{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":134,"sex":16,"minAge":47,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":21,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":126},"100575727","upper-airway-inflammation-and-olfaction-mechanisms-of-loss-and-recovery-100575727","NCT06776042","Upper Airway Inflammation and Olfaction: Mechanisms of Loss and Recovery","IMMUNODOR","Inclusion Criteria:\n\n* At least two of the following symptoms: nasal obstruction, rhinorrhoea, smell loss, facial pain for 12 weeks.\n* Endoscopic visualisation of bilateral sinonasal polyps\n* SSI (TDI) \\\u003C 30.75 and decreased sense of smell subjectively\n* Eosinophilia \\> 300\u002Fμl of blood Ku\u002Fl\n* On a stable nasal steroid treatment for at least 4 weeks\n\nExclusion Criteria:\n\n* Active smoking\n* Primary and secondary immune deficiencies\n* Ciliary diseases (cystic fibrosis, primary ciliary diskinesia)\n* History of or current nasal malignancies\n* \\\u003C 18 years and \\> 70 years\n* Patients unable to express consent\n* Use of systemic corticosteroids for \\\u003C 4 weeks before visit 1 • Use of systemic or local antibiotics for \\\u003C 4 weeks before visit 1",true,"70 Years",{"count":137,"type":20},140,[101],"The goal of this clinical trial is to understand the mechanisms leading to olfactory dysfunction (OD) in chronic rhinosinusitis (CRS). The main questions it aims to answer are:\n\n* Is the type 2 inflammation impacting the olfactory epithelium regeneration, leading to OD?\n* Does a treatment interfering with one of the major T2 inflammatory cytokines, have an impact on the mechanisms of OD in CRS?\n\nParticipants will undergo olfactory testing and nasal brushing before and after 3 months of treatment.",[26],"2026-04-24",{"date":143,"type":31},"2026-04-27",{"date":145,"type":31},"2023-05-22",{"date":147,"type":20},"2026-09-30",{"name":149,"class":125},"Cliniques universitaires Saint-Luc- Université Catholique de Louvain",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":21,"phases":160,"briefSummary":161,"conditions":162,"keywords":163,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":126},"100633241","phenotyping-of-type-2-inflammation-profile-by-rheology-of-nasal-secretions-and-tissue-quantification-of-eosinophilic-polymorphonuclear-cells-in-the-middle-turbinate-100633241","NCT07524127","Phenotyping of Type 2 Inflammation Profile by Rheology of Nasal Secretions and Tissue Quantification of Eosinophilic Polymorphonuclear Cells in the Middle Turbinate","PheRhEos","Inclusion Criteria:\n\n* Patient requiring sinonasal surgery\n* For patients in the CRSwNP group:\n\nPresence of nasal polyposis defined according to EPOS 2020 recommendations:\n\nClinical examination revealing, for at least 12 weeks prior to inclusion, 2 or more of the following symptoms:\n\n* Nasal congestion\n* Rhinorrhea (anterior\u002Fposterior)\n* Or a Facial pain\u002Fpressure\n* Or a Reduced or lost sense of smell AND visible polyps in both nasal cavities on endoscopic examination of the middle meatus (regardless of size).\n\nExclusion Criteria:\n\n* Inability to provide a sinonasal secretion sample by blowing\n\n  * Conditions causing secondary nasal polyposis (e.g., cystic fibrosis, ciliary dyskinesia, immune disorders, allergic fungal sinusitis)\n  * Illiteracy\n  * Lack of consent\n  * Legal protection status (guardianship, curatorship, etc.)\n  * No social security coverage\n  * Persons deprived of liberty by judicial or administrative decision\n  * Participation in another study with an ongoing exclusion period","85 Years",{"count":159,"type":20},60,[101],"This monocentric, interventional study (category RIPH2) aims to characterize the rheological properties of sinonasal secretions in patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). The primary objective is to determine differences in mucus viscosity between CRSwNP patients and a control group. By establishing a correlation between local rheology and systemic Type 2 inflammation biomarkers, the study seeks to develop a non-invasive, rapid \"point-of-care\" tool to refine patient phenotyping and improve the personalization of biological treatments.",[26],[164,165,166,167],"Rheology","Nasal Polyposis","mucus","T2 inflammation","2026-04-09",{"date":170,"type":31},"2026-04-13",{"date":172,"type":20},"2026-08-01",{"date":174,"type":20},"2028-05-01",{"name":176,"class":125},"University Hospital, Montpellier",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":134,"sex":16,"minAge":47,"maxAge":97,"enrollmentInfo":184,"targetDuration":4,"studyType":21,"phases":186,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":200},"100626539","phase-1-a-study-of-bbt002-in-healthy-volunteers-hvs-and-in-patients-with-chronic-rhinosinusitis-with-nasal-polyps-crswnp-and-comorbid-asthma-100626539","NCT07436949","A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) and Comorbid Asthma","A Randomized, Double-Blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics,Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in Healthy Volunteers and Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) and Comorbid Asthma","Inclusion Criteria: Part (A\\&B):\n\n1. Age of 18-55 years (HVs), 18-75 years (patients)\n2. Body mass index between 18-30 kg\u002Fm², capped at 120 kg\n3. Negative pregnancy tests for women of childbearing potential\n4. Willingness to refrain from alcohol consumption for 24 hours prior to each study visit\n5. Non-smokers, healthy current smokers (≤5 cigarettes\u002Fday), or ex smokers\n\nKey Inclusion Criteria (Part B only)\n\n1. Participants with physician-diagnosed CRSwNP for at least 12 months prior to randomization\n2. SNOT-22 total score ≥30 at screening and randomization.\n3. Documented systemic corticosteroid use (or contraindication\u002Fintolerance) within past 24 months.\n4. Diagnosed asthma per GINA 2025, stable for ≥12 months. Stable on GINA Step 3 or higher therapy for 6 weeks before screening.\n\nExclusion Criteria:Part (A\\&B):\n\n1. Positive viral serology for human immunodeficiency virus (HlV), hepatitis C virus (HCV), or hepatitis B (HBV)\n2. Immunodeficiencies, autoimmune diseases, or cancer, history of conditions predisposing to infections\n3. History of major metabolic, dermatological, liver, kidney, hematological or other significant disorders\n4. Clinically relevant abnormal lab results, including low blood counts, liver enzymes, or abnormal kidney function\n5. Positive drug\u002Falcohol tests or abnormal vital signs at screening or Day -1\n6. Abnormal Electrocardiogram(ECG) findings\n7. History of drug\u002Falcohol abuse in the past 2 years\n8. History of severe allergic reactions or hypersensitivity\n\nKey Exclusion Criteria for (Part B only):\n\n1. Any sinus\u002Fnasal surgery (including polypectomy) within 6 months before screening, History of ≥2 prior sinus\u002Fnasal surgeries\n2. Concurrent nasal conditions that may interfere with study assessments\n3. Significant or unstable cardiovascular diseases\n4. Recent clinically significant infection",{"count":185,"type":20},64,[187,188],"PHASE1","PHASE2","This study is a randomized, double-Blind, placebo-controlled, Single and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in Healthy Volunteers and Participants with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and Comorbid Asthma.",[26],"2026-02-22",{"date":193,"type":31},"2026-02-27",{"date":195,"type":20},"2026-03-02",{"date":197,"type":20},"2027-05-30",{"name":199,"class":38},"Bambusa Therapeutics",12,{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":97,"enrollmentInfo":208,"targetDuration":4,"studyType":21,"phases":210,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":126},"100617076","phase-2-a-study-to-evaluate-the-efficacy-and-safety-of-lp-003-injection-in-patients-with-chronic-rhinosinusitis-with-nasal-polyps-crswnp-100617076","NCT07313917","A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase Ⅱ Clinical Trial to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)","Inclusion Criteria:\n\n1. Capable of understanding the study and voluntarily signing the Informed Consent Form (ICF);\n2. Aged 18 to 75 years (inclusive) at the time of signing the ICF, regardless of gender;\n3. Diagnosis of bilateral chronic rhinosinusitis with nasal polyps (CRSwNP);\n4. Persistence of the following symptoms for ≥ 4 weeks prior to the screening\u002Frun-in period:\n\n   * Nasal congestion;\n   * Any one of the other symptoms: mucoid or mucopurulent nasal discharge, head and facial distension\u002Fpain, hyposmia or anosmia;\n5. Nasal Polyp Score (NPS) ≥ 5 points, with each nasal cavity scoring at least ≥ 2 points during the screening\u002Frun-in period and prior to randomization;\n6. Participants report moderate to severe nasal congestion during the screening\u002Frun-in period and prior to randomization:\n\n   * Nasal Congestion Score (NCS) of 2 or 3 points at the screening\u002Frun-in period (Visit 1, V1);\n   * Mean weekly NCS ≥ 2 points prior to randomization;\n7. With bilateral CRSwNP despite prior treatment with systemic corticosteroids (SCS) such as oral corticosteroids (OCS) within 2 years prior to screening; and\u002For has contraindications to SCS treatment or is intolerant to SCS; and\u002For has undergone nasal polypectomy within 6 months prior to screening, with persistent bilateral CRSwNP.\n8. Has been on a stable dosage of intranasal corticosteroids (INCS) for at least 4 weeks prior to screening;\n9. Demonstrates ≥80% adherence to mometasone furoate nasal spray (MFNS) administration during the run-in period (with a minimum of 14 days of use).\n\nExclusion Criteria:\n\n1. Concurrent other nasal diseases or nasal symptoms;\n2. Acute upper respiratory tract infection at screening, which the investigator assesses may affect nasal symptom scoring;\n3. Severe infection requiring intravenous antibiotics and\u002For hospitalization within 4 weeks prior to randomization that has not yet resolved, or active infection requiring oral antibiotics within 2 weeks prior to randomization that has not yet resolved; the investigator assesses that enrollment of the participant may pose uncontrollable risks;\n4. Concurrent active parasitic infection (e.g., helminths) or suspected parasitic infection;\n5. Known or suspected history of immunosuppression, including a history of invasive opportunistic infections (e.g., histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis); or participants with a history of such infections that have resolved but are assessed by the investigator as likely to recur frequently;\n6. Any severe or unstable disease that the investigator believes may affect the participant's safety during the study and\u002For hinder the participant from completing the study;\n7. Has any severe or unstable disease that, in the investigator's judgment, may affect the safety of the trial participant during the study and\u002For preclude the participant from completing the study, including but not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, autoimmune, hematological, or psychiatric disorders.\n8. Current or prior receipt of the following treatments:\n\n   * Use of traditional Chinese medicine (TCM) or proprietary Chinese medicines for chronic rhinosinusitis within 1 week prior to screening;\n   * Use of medium- or short-acting systemic corticosteroids (SCS) within 4 weeks prior to randomization, or long-acting SCS within 6 weeks prior to randomization;\n   * Receipt of any systemic monoclonal antibody therapy \\[e.g., Stapokibart, Dupilumab, Mepolizumab, Omalizumab, Tezepelumab, etc.\\] within 10 weeks prior to randomization or within 5 half-lives (whichever is longer);\n   * Use of systemic immunosuppressants within 4 weeks prior to randomization or within 5 half-lives (whichever is longer);\n   * Initiation of leukotriene receptor antagonist (LTRA) therapy within 4 weeks prior to randomization (participants who have been receiving stable-dose LTRA therapy for at least 4 weeks prior to randomization are eligible for enrollment);\n9. For participants with concurrent asthma, the forced expiratory volume in 1 second (FEV1) as a percentage of predicted value ≤ 50% during the screening\u002Frun-in period;\n10. Known allergy or intolerance to any component of the investigational product and\u002For mometasone furoate nasal spray;\n11. Pregnant or lactating females;\n12. Any other conditions that the investigator deems inappropriate for the participant to participate in the study.",{"count":209,"type":20},150,[188],"This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase II clinical trial. Its primary objective is to explore and preliminarily evaluate the efficacy and safety of LP-003 Injection in the treatment of participants with chronic rhinosinusitis with nasal polyps (CRSwNP), as well as to investigate its pharmacokinetic (PK), pharmacodynamic (PD) profiles, and immunogenicity.",[26],"2026-02-04",{"date":215,"type":31},"2026-02-06",{"date":217,"type":20},"2026-01-20",{"date":219,"type":20},"2027-09-30",{"name":221,"class":38},"Longbio Pharma",{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":230,"enrollmentInfo":231,"targetDuration":4,"studyType":21,"phases":233,"briefSummary":234,"conditions":235,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":126},"100602597","real-time-diagnosis-of-eosinophilic-nasal-polyps-using-high-sensitivity-spectroscopy-100602597","NCT07125586","Real-Time Diagnosis of Eosinophilic Nasal Polyps Using High-Sensitivity Spectroscopy","Evaluation of Efficacy and Safety of a Real-time Typing Diagnosis System for Eosinophilic Nasal Polyps Based on High-sensitivity Spectroscopy Technology","REDENP","Inclusion Criteria:\n\n1. Male and female subjects aged 18 to 65 years old\n2. Subjects diagnosed with CRSwNP by nasal endoscopy, CT, or MRI preoperatively (in accordance with the diagnostic criteria of EPOS 2020)\n3. Normal coagulation function (prothrombin time \\[PT\\], activated partial thromboplastin time \\[APTT\\], and platelet count are within the normal range)\n4. No severe cardiopulmonary dysfunction or other comorbidities that affect the tolerance of general anesthesia and surgery\n5. Women of childbearing age must take appropriate medical contraceptive measures during the study period and within 4 weeks after the end of the trial treatment\n6. Patients with good compliance, who voluntarily participate in this clinical study and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with other nasal and paranasal sinus diseases excluding chronic rhinosinusitis (such as nasal tumors, fungal sinusitis, and post-traumatic nasal deformities)\n2. Patients with coagulation dysfunction, immunodeficiency, or long-term use of anticoagulant\u002Fantiplatelet drugs at the time of visit, and females during menstruation\n3. Patients who have taken oral glucocorticoids within 1 month prior to the visit\n4. Patients with a history of nasal endoscopic surgery or nasal radiotherapy\n5. Pregnant or lactating women, or those with severe systemic diseases (such as uncontrolled hypertension, diabetes, hepatic or renal insufficiency)\n6. Patients with incomplete clinical data or missing postoperative follow-up data\n7. Any other conditions deemed by the researcher as making the subject unsuitable for participating in the trial\n8. Patients with poor treatment compliance","65 Years",{"count":232,"type":20},353,[101],"Chronic rhinosinusitis with nasal polyps (CRSwNP) is a common condition causing nasal congestion, discharge, and reduced sense of smell, seriously affecting patients' quality of life. A subtype called eosinophilic CRSwNP (eCRSwNP) is difficult to treat and often recurs after surgery.\n\nCurrently, diagnosing this subtype requires tissue samples after surgery, which delays treatment decisions and may lead to unnecessary surgeries. Our research team has developed a new, non-invasive diagnostic system using advanced spectral technology to detect a natural fluorescence marker inside eosinophils (a type of immune cell) in nasal polyps. This system can quickly identify eCRSwNP before surgery by shining a safe light on the nasal tissue and analyzing the fluorescence signals.\n\nThis study aims to evaluate how accurate and safe this real-time diagnostic system is in clinical practice. If successful, it will help doctors choose better personalized treatments, reduce unnecessary surgeries, lower recurrence rates, and ultimately improve patients' lives.",[26],"2025-12-23",{"date":238,"type":31},"2025-12-30",{"date":240,"type":31},"2025-08-26",{"date":242,"type":20},"2028-06-01",{"name":244,"class":125},"The Affiliated Hospital of Qingdao University",{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":97,"enrollmentInfo":252,"targetDuration":4,"studyType":21,"phases":254,"briefSummary":255,"conditions":256,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":159},"100601189","phase-3-clinical-trial-of-tqc2731-injection-in-patients-with-chronic-sinusitis-and-nasal-polyps-100601189","NCT07107256","Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)","Inclusion Criteria:\n\n* Signed informed consent form prior to trial participation, demonstrating full understanding of trial objectives, procedures, and potential adverse reactions.\n* Age between 18 and 75 years (inclusive) at the time of informed consent signing, regardless of gender.\n* Diagnosis of bilateral chronic rhinosinusitis with nasal polyps (CRSwNP) meeting the diagnostic criteria of the \"Chinese Guidelines for the Diagnosis and Treatment of Chronic Rhinosinusitis (2018)\"\n* At least one prior course of systemic corticosteroids (prednisone 0.5-1 mg\u002Fkg\u002Fday or 15-30 mg\u002Fday or equivalent for minimum 5 days) within 2 years before screening, with persistent bilateral CRSwNP; AND\u002FOR contraindication\u002Fintolerance to systemic corticosteroids; AND\u002FOR prior nasal polyp surgery performed more than 6 months before screening.\n* Bilateral Nasal Polyp Score (NPS) ≥5 (maximum score 8) with ≥2 points per nostril, as assessed by nasal endoscopy during screening and randomization.\n* Nasal Congestion Score (NCS) ≥2 at screening (daily average) and randomization (weekly average).\n* Persistent symptoms of rhinorrhea and\u002For hyposmia\u002Fanosmia for over 8 weeks prior to screening.\n* 22-item Sino-Nasal Outcome Test (SNOT-22) score ≥30 at screening and randomization.\n* Stable dose of intranasal corticosteroids (INCS) for \\>4 weeks prior to screening (subjects using non-mometasone furoate nasal spray \\[MFNS\\] products must agree to switch to Mometasone Furoate Nasal Spray (MFNS) during the study).\n* Subjects with comorbid asthma must have had stable asthma symptoms for ≥4 weeks prior to screening (if using medications, such as inhaled corticosteroids, the same dose must have been stably maintained for ≥4 weeks before screening, and the dose is assessed to remain stable during the first phase).\n* The evaluation during the lead-in period showed that the medication adherence to intranasal mometasone furoate nasal spray (MFNS) was greater than 70%, and the adherence to daily symptom assessment records in the subjects' electronic logs was also greater than 70%. Note: Days with missing electronic log data were considered non-adherent to this criterion.\n* Agreement to practice effective non-pharmacologic contraception from informed consent until 6 months post-final dose, for subjects\u002Fpartners of childbearing potential.\n\nExclusion Criteria:\n\n* Conditions\u002FDiseases Affecting Efficacy Evaluation\n\n  * Nasal septum deviation causing ≥1 nostril obstruction；\n  * Perforation of the nasal septum\n  * Acute sinusitis, nasal infection, or upper respiratory infection within 2 weeks pre-screening or during screening\u002Frun-in periods；\n  * Rhinitis medicamentosa；\n  * Eosinophilic granulomatosis with polyangiitis (EGPA), granulomatosis with polyangiitis (GPA), Young's syndrome, Kartagener's syndrome, other ciliary dyskinesia syndromes, or cystic fibrosis；\n  * Suspected or confirmed fungal sinusitis by imaging；\n  * Prior nasal surgery altering lateral wall structure precluding NPS assessment；\n  * Nasal malignancies or benign tumors (e.g., papilloma, hemangioma)；\n* Any intranasal and\u002For sinus surgery (including polypectomy) within 6 months prior to screening.\n* Uncontrolled epistaxis within 2 months prior to screening.\n* Regular use of decongestants (topical or systemic) prior to screening, except for short-term use during endoscopic examinations.\n* Patients who have received any of the following treatments prior to randomization:\n\n  * Treatment with immunosuppressants (including but not limited to: cyclophosphamide, cyclosporine, interferon gamma, azathioprine, methotrexate, mycophenolate, tacrolimus, Secukinumab) within 8 weeks or 5 half-lives prior to screening (whichever is longer)；\n  * Treatment with any monoclonal antibodies (including but not limited to: benralizumab, mepolizumab, omalizumab, dupilumab, or other similar drugs \\[e.g., TSLP blockers\\]) within 8 weeks or 5 half-lives prior to screening (whichever is longer).\n  * Patients who used medium- or short-acting systemic corticosteroids (SCS, including oral, intravenous, or intramuscular administration), systemic traditional Chinese medicine preparations for treating CRS within 4 weeks prior to screening, or received long-acting SCS (e.g., triamcinolone acetonide injection) within 6 weeks prior to screening, or who plan to receive the aforementioned medications during the study period.\n  * Use of corticosteroid-eluting nasal stents within 6 months prior to screening;\n  * Treatment with immunoglobulins or blood products within 28 days prior to screening;\n  * Administration of live attenuated vaccines within 28 days prior to screening or planned during the study period;\n  * Allergen-specific immunotherapy within 6 months prior to screening (allowed only if: initiated \\>3 months before screening, maintained at a stable dose for ≥1 month before Visit 1, and no planned dose changes during the study)；\n  * Participation in other drug\u002Fmedical device clinical trials within 3 months prior to screening (based on last administration\u002Fuse).\n  * Use nasal antihistamines (such as olopatadine nasal spray, azelastine nasal spray, levocabastine nasal spray, etc.) for the first 3 days.\n* Screening for a history of active pulmonary tuberculosis within the past 12 months；\n* Exclusion of infections within the last 14 days requiring systemic antibiotic, antiviral, antifungal, antiparasitic, or antiprotozoal therapy;\n* Exclusion of subjects diagnosed with helminthic parasitic infection in the past 6 months who either did not receive standard treatment or had treatment failure；\n* Known or suspected history of immunosuppression, immune dysfunction, or immune dysregulation, including but not limited to invasive opportunistic infections (histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis), even if the infection has resolved; Or there is an unusual frequency, recurrence, or prolonged infection (as judged by the investigator).\n* The forced expiratory volume in the first second (FEV1) of the subjects during the screening\u002Fintroduction period was ≤ 50% of the normal predicted value.\n* Patients with comorbid asthma who meet any of the following criteria:\n\nAsthma exacerbation within 90 days before screening, or current use of inhaled corticosteroids (ICS) at a daily dose higher than 1000μg fluticasone (or equivalent).\n\nDefinition of Asthma Acute Exacerbation:\n\n* Use of systemic corticosteroids (or a temporary increase in the stable dose of baseline OCS) for at least 3 consecutive days due to worsening asthma; a single injection of depot long-acting corticosteroids may be considered equivalent to a 3-day course of systemic corticosteroids.\n* An emergency department or urgent care center visit due to asthma requiring systemic corticosteroids (as described above) (defined as evaluation and treatment in the emergency department or urgent care center lasting \\\u003C24 hours).\n* Hospitalization due to asthma (defined as admission to a medical facility and\u002For evaluation and treatment in a healthcare setting lasting ≥24 hours).\n\n  * Use of leukotriene antagonists\u002Fmodulators prior to randomization (subjects who have been on a stable dose of leukotriene modulators for ≥30 days continuously prior to randomization may be enrolled);\n  * Presence of other concurrent active or clinically significant respiratory diseases that, in the investigator's judgment, may significantly impact the study, such as active tuberculosis, lung cancer, bronchiectasis, pulmonary sarcoidosis, pulmonary fibrosis, pulmonary hypertension, interstitial lung disease, or other active pulmonary conditions\n  * Subjects who have undergone lobectomy or lung volume reduction surgery within 12 months prior to the start of the study;\n  * Exclusion of subjects with cardiovascular conditions (including but not limited to unstable ischemic heart disease, heart failure, uncontrolled hypertension, myocardial infarction, significant arrhythmias, long QT syndrome, or Fridericia-corrected QT interval (QTcF) prolongation \\[≥450 ms in men, ≥470 ms in women\\]) if the investigator deems participation could compromise safety or study outcome interpretation;\n  * Exclude individuals with difficult venous access or a history of vasovagal syncope (needle\u002Fblood-related);\n  * Exclusion of any current active malignancy or history of malignancy (Patients with basal cell carcinoma, localized squamous cell carcinoma of the skin, or carcinoma in situ of the cervix are eligible if curative treatment was completed \\>12 months before V1. Patients with other malignancies are eligible if curative treatment was completed at least 5 years before V1).\n  * Presence of active autoimmune diseases (including but not limited to Hashimoto's thyroiditis with hyperthyroidism, Graves' disease, inflammatory bowel disease, primary biliary cholangitis, systemic lupus erythematosus, multiple sclerosis and other neuroinflammatory disorders, psoriasis vulgaris, and rheumatoid arthritis);\n  * Exclusion if any infectious disease screening indicator meets the following criteria during screening;\n* Exclusion of subjects who are positive for hepatitis B virus surface antigen (HBsAg).\n* Hepatitis B virus core antibody (HBcAb) with detectable Hepatitis B Virus (HBV)-DNA.\n* Exclude if Hepatitis C Virus (HCV) antibody-positive and HCV-RNA positive, or if previously treated for HCV (regardless of current HCV-RNA status).\n* Anti-Treponema pallidum antibody (Anti-TP) positive (if syphilis serology is positive, a non-treponemal test must be performed; subjects with a negative non-treponemal test and deemed by the investigator as previously cured are eligible).\n* Anti-HIV positive\n\n  * Abnormal laboratory test results:\n* White blood cell count \\\u003C3.5 × 10⁹\u002FL;\n* Aspartate aminotransferase (AST) \\>2.5 × upper limit of normal (ULN);\n* Alanine aminotransferase (ALT) \\>2.5 × ULN;\n* Total bilirubin \\>2 × ULN;\n* Creatinine \\>1.5 × ULN\n\n  * Any clinically significant abnormal findings during the import period, including physical examination, vital signs, 12-lead ECG, blood biochemistry, hematology, or urinalysis, which in the investigator's judgment may place the patient at risk, affect study results, or impair the patient's ability to complete the entire study\n  * Women who are pregnant or lactating.\n  * Those who were still smokers or had quit smoking for less than six months at the time of screening.\n  * Exclude those with regular excessive alcohol consumption (\\>14 units\u002Fweek for females or \\>21 units\u002Fweek for males) in the past 6 months, inability to abstain during the trial, or a positive breath alcohol test.\n  * History of drug abuse within the past 2 years, or a positive drug abuse screening result.\n  * Subjects with a known history of hypersensitivity or allergic reaction to any ingredient of mometasone furoate nasal spray (Nasonex®) or TQC2731 injection.\n  * Exclusion for any history of systemic allergic reaction to biologic agents (local injection site reactions excluded).\n  * The participant demonstrated poor adherence and was deemed unable to complete the study.\n  * Any medical or psychiatric condition that, in the judgment of the investigator or the sponsor's medical reviewer, may affect the subject's safety throughout the study or impede the subject's ability to complete the entire study process or interfere with the interpretation of study results, including but not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematologic disorders, psychiatric illnesses, or major physical disabilities.",{"count":253,"type":20},246,[23],"TQC2731 injection is a humanized monoclonal antibody that targets Thymic Stromal Lymphopoietin (TSLP), blocks the TSLP pathway, and inhibits the production of downstream cytokines, thereby exerting anti-inflammatory effects. The purpose of this study is to evaluate the efficacy and safety of TQC2731 injection in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).",[26],"2025-12-09",{"date":259,"type":31},"2025-12-16",{"date":261,"type":31},"2025-09-25",{"date":263,"type":20},"2027-09",{"name":265,"class":38},"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.",{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":97,"enrollmentInfo":273,"targetDuration":4,"studyType":21,"phases":275,"briefSummary":277,"conditions":278,"keywords":279,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":295},"100608344","phase-4-anti-il-5-therapy-with-simple-polypectomy-versus-extended-endoscopic-sinus-surgery-for-crswnp-100608344","NCT07200336","Anti-IL-5 Therapy With Simple Polypectomy Versus Extended Endoscopic Sinus Surgery for CRSwNP","Efficacy of Anti-IL-5 Therapy Combined With Simple Polypectomy Versus Extended Endoscopic Sinus Surgery in Patients With CRSwNP: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. Endoscopy shows bilateral nasal polyps, with bilateral NPS ≥4 (≥2 per side)\n2. Nasal obstruction symptoms \\>3 months, nasal obstruction score ≥2 (total 3 points) and\u002For hyposmia ≥2 (maximum 3 points)\n3. Evidence of type 2 inflammation: Nasal polyp tissue Eos \\>55\u002FHPF or \\>27% of inflammatory cells; or Peripheral blood Eos ≥6.9% (without asthma) or ≥3.7% (with asthma) Note: Meet any 2 of the above 3 criteria\n4. Failure after 4 weeks of standard medical therapy including: Intranasal corticosteroids \\>4 weeks; Other agents (oral steroids, macrolides, antihistamines, leukotriene receptor antagonists, decongestants, antibiotics) permitted as needed\n\nExclusion Criteria:\n\n1. Cystic fibrosis, Young's syndrome, Kartagener syndrome, antrochoanal polyp, or rhinitis medicamentosa\n2. Acute upper respiratory infection within 2 weeks\n3. Asthma exacerbation within 1 month\n4. HIV infection\n5. Parasitic infection within 6 months\n6. History of hypersensitivity to investigational drugs (except aspirin intolerance)\n7. Hypersensitivity to monoclonal antibodies or anti-IL-5 agents\n8. Oral steroid therapy within 1 month\n9. Pregnancy planning, current pregnancy, or lactation\n10. Uncontrolled systemic diseases\n11. Have a history of previous sinus surgery for CRSwNP\n12. Significant septal deviation affecting unilateral ventilation (mild deviation allowed)\n13. Investigator judgment of unsuitability for cohort study",{"count":274,"type":20},360,[276],"PHASE4","This study compares two surgical approaches combined with anti-IL-5 therapy in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Patients will be randomly assigned to one of the three groups: (1) anti-IL-5 alone, (2) anti-IL-5 with simple polyp removal, or (3) anti-IL-5 with extended sinus surgery. The aim of this study is to see if a less invasive surgery (simple polyp removal) with anti-IL-5 works as well as more extensive surgery with anti-IL-5. Participants will be followed for 1 to 3 years.",[26],[280,281,282,283,284,285],"Anti-IL-5","Biologic-Surgical Combination","Extended Sinus Surgery","SNOT-22","Type 2 Inflammation","Recurrence","2025-09-29",{"date":288,"type":31},"2025-10-01",{"date":290,"type":20},"2025-10-08",{"date":292,"type":20},"2031-10-10",{"name":294,"class":125},"Eye & ENT Hospital of Fudan University",17,{"id":297,"slug":298,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":303,"targetDuration":4,"studyType":21,"phases":305,"briefSummary":306,"conditions":307,"keywords":308,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":4},"100603297","implementation-of-a-joint-pulmonologist-and-ent-consultation-in-the-care-pathway-of-patients-suffering-from-asthma-and-chronic-rhinosinusitis-with-nasal-polyposis-effectiveness-compared-with-consultations-by-specialty-con-po-study-100603297","NCT07134686","Implementation of a Joint Pulmonologist and ENT Consultation in the Care Pathway of Patients Suffering From Asthma and Chronic Rhinosinusitis With Nasal Polyposis: Effectiveness Compared With Consultations by Specialty (CON-PO Study).","CON-PO","Inclusion Criteria:\n\n* Male or female, 18 years of age or older;\n* With a diagnosis of asthma;\n* With a diagnosis of chronic rhinosinusitis with nasal polyposis;\n* Whose asthma and\u002For chronic rhinosinusitis is\u002Fare not controlled according to SNOT-22 and ACQ-6 scores;\n* Having used systemic corticosteroids in the previous year to treat symptoms related to one of these conditions at least;\n\nExclusion Criteria:\n\n* Patient in a period of exclusion from another research protocol at the time of consent signature;\n* Subjects covered by articles L1121-5 to 1121-8 of the French Public Health Code (adult patients under guardianship or curatorship, patients deprived of their liberty, pregnant or breast-feeding women);\n* Patients who do not read and\u002For understand French",{"count":304,"type":20},195,[101],"Asthma affects the lower respiratory tract (bronchi), whereas chronic rhinosinusitis with nasal polyposis (CRSwNP) involves the upper airways. Despite this anatomical distinction, the upper and lower airways form a continuous respiratory tract and share common pathophysiological mechanisms. Consequently, asthma and CRSwNP frequently coexist, and several therapeutic strategies are effective for both conditions.\n\nGiven these overlaps, we hypothesize that a multidisciplinary consultation involving both a pulmonologist and an ENT specialist could be more effective than separate consultations for patient care. We also believe that this innovative organization that would benefit the healthcare system.\n\nTo test this hypothesis, we are conducting a study whose primary objective is to assess whether joint consultations lead to a reduction in oral corticosteroid need over the year following the initial consultation, by enabling more personalized treatment strategies.\n\nSecondary outcomes will include the frequency of asthma exacerbations, frequency of ENT-related events, respiratory symptoms, quality of life, and healthcare ressources utilization.\n\nWe will compare outcomes between two patient groups: one receiving joint consultation from both specialists, and the other managed through standard, separate consultations as per current clinical practice.",[79,26],[79,309,310],"Care pathway","Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)","2025-09-19",{"date":313,"type":31},"2025-09-22",{"date":315,"type":20},"2025-11-01",{"date":317,"type":20},"2028-11",{"name":319,"class":125},"Assistance Publique Hopitaux De Marseille",{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":328,"enrollmentInfo":329,"targetDuration":4,"studyType":21,"phases":331,"briefSummary":332,"conditions":333,"keywords":335,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":344,"leadSponsor":346,"locationsCount":126},"100596488","effect-of-tezepelumab-on-barrier-function-in-severe-asthmatic-patients-with-and-without-comorbid-chronic-rhinosinusitis-with-nasal-polyps-100596488","NCT07046117","Effect of Tezepelumab on Barrier Function in Severe Asthmatic Patients With and Without Comorbid Chronic Rhinosinusitis With Nasal Polyps","Effect of Tezepelumab on Barrier Function in Severe Asthmatic Patients With and Without Comorbid Chronic Rhinosinusitis With Nasal Polyps - an Exploratory Study","Tezebarrier","Inclusion Criteria:\n\n1. Provision of informed consent prior to any study specific procedures\n2. Age 18-99 years and willing to participate in the study\n3. Have a recorded clinical diagnosis of asthma (ICD-10 Code: J45)\n4. Undergo severe asthma treatment according to GINA\u002FDAL treatment step 4 or 5\n5. Meet the requirements for treatment of severe asthma with Tezepelumab defined as:\n\n   * severe asthma that remains uncontrolled despite a high dosage of ICS\u002FLABA, or that requires a high dose to prevent it from becoming uncontrolled. One of the following criteria needs to be fulfilled:\n\n     * ACT \\\u003C20, ACQ\\>0.75\n     * During the last 12 months 2 courses of OCS for at least 3 days due to severe asthma symptoms\n     * During last 12 months one exacerbation requiring hospitalization\n     * Lung function: FEV1 \\\u003C80% predicted\n   * FeNO ≥ 20 ppB\n   * had either ≥250 eosinophils \u002Fµl measured in the blood OR measurement of blood eosinophils ≥150 cells during reduction of OCS dosing or high dose ICS and\u002For one measurement of sputum eosinophils \\> 2% or BAL eosinophils \\> 2%\n   * Group with polyps: Presence of nasal polyps as confirmed by endoscopy or CT according to the European Position Paper on Rhinosinusitis and Nasal Polyps Guidelines\n6. mucus score of ≥ 1\n7. Patients with a history of treatment with monoclonal antibodies for asthma or polyps will only be included if at least a washout period of 3 half-lives or 3 months have passed (whichever is longer)\n\nExclusion Criteria:\n\n* 1\\. Patients with current therapy with biologics as well as therapy with biologics 12 weeks (3 half-lives) before the start of the study or history of therapy with tezepelumab 2. Pregnancy (as determined by urine pregnancy test) 3. Patients with severe anatomic variations or deviations that do not allow access to all areas in the nasal cavity or to perform bronchoscopy 4. Patients with any other confounding underlying lung disorder including but not limited to:\n\n  * Bronchiectasis, pulmonary fibrosis, emphysema, primary ciliary dyskinesia\n  * Cystic fibrosis, any known parasitic infections and lung cancer\n\n    5\\. Patients with other causes of nasal polyps than Type 2 CRS inflammation 6. Patients with pulmonary conditions with symptoms of asthma and blood eosinophilia including but not limited to: Eosinophilic granulomatosis with polyangiitis (EGPA) allergic bronchopulmonary aspergillus and hypereosinophilic syndrome 7. Contraindications for endobronchial and\u002For transbronchial biopsy. 8. A mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study 9. Patients with clinically meaningful comorbidity as determined by the evaluating committee 10. Immunosuppressive treatment (e.g. cyclosporine) 11. Drug and alcohol abuse 12. Current smoker and former smokers if stopped smoking \\\u003C6 months","99 Years",{"count":330,"type":20},20,[101],"In this study, we will investigate the effect of tezepelumab on the epithelial barrier function of the upper and lower airways in patients suffering from severe asthma with and without chronic rhinosinusitis with nasal polyps. This will be achieved by analysis of epithelial barrier function upon challenge with various harmful substances (e.g. cigarette smoke extract, allergens) in cultured primary respiratory tract epithelial cells. Furthermore we will assess changes in clinical parameters, cellular composition and inflammatory mediators.",[334,26],"Asthma Bronchiale",[336,105,337,338,339],"asthma","tezepelumab","epithelial barrier","airways","2025-06-30",{"date":342,"type":31},"2025-07-01",{"date":288,"type":20},{"date":345,"type":20},"2028-08-01",{"name":347,"class":125},"Medical University of Vienna",{"id":349,"slug":350,"hasResults":11,"nctId":351,"briefTitle":352,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":97,"enrollmentInfo":354,"targetDuration":4,"studyType":21,"phases":356,"briefSummary":357,"conditions":358,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":126},"100577673","phase-4-a-cohort-study-on-biomarkers-to-predict-the-efficacy-of-biologics-for-chronic-rhinosinusitis-with-nasal-polyps-100577673","NCT06801353","A Cohort Study on Biomarkers to Predict the Efficacy of Biologics for Chronic Rhinosinusitis with Nasal Polyps","Inclusion Criteria:\n\n1. Age 18-75 years old.\n2. With bilateral chronic rhinosinusitis with nasal polyposis.\n3. Nasal Polyp Score ≥4 (minimum score of 2 per nasal cavity) at baseline.\n4. Nasal congestion score ≥2 at baseline.\n5. Patients who have received systemic corticosteroids (SCS) treatment within 2 years before screening, and\u002For have contraindications or intolerance to SCS treatment, and\u002For received surgical for nasal polyps more than 6 months before screening.\n6. Have been using intranasal corticosteroids (INCS) at a stable dose for at least 4 weeks before screening.\n7. Symptoms of nasal obstruction and additional symptoms such as loss of smell or rhinorrhea should be present for at least 4 weeks before screening.\n8. Good adherence.\n\nExclusion Criteria:\n\n1. Not enough washing out period for prior biological therapy (within 10 weeks or 5 half-lives \\[whichever is longer\\] before baseline).\n2. Use of systemic immunosuppressants for inflammatory diseases or autoimmune diseases within 8 weeks or 5 half-lives before baseline (whichever is longer).\n3. Initiation of leukotriene receptor antagonist treatment, oral glucocorticoid treatment, or traditional Chinese medicine treatment for chronic rhinosinusitis within 4 weeks before baseline.\n4. Subjects who have undergone surgery that changed the nasal structure and cannot be evaluated for Nasal Polyp Score.\n5. Participants with a forced expiratory volume in 1 second (FEV1) ≤50% of predicted normal during screening\u002Frun-in period.\n6. Hypersensitivity to MFNS or anti-IL-4R monoclonal antibodies or stapokibart components.\n7. Concomitant with other poorly controlled serious diseases or recurrent chronic diseases.\n8. Women who are pregnant, breastfeeding, or planning either during the study.",{"count":355,"type":20},90,[276],"Recently, several biologic therapies have become available for treating chronic rhinosinusitis with nasal polyps (CRSwNP). However, not every patient responds to these treatments. This clinical trial aims to develop a non-invasive predictive model to help determine how effective IL-4Rα targeted monoclonal antibody therapy will be for individuals with CRSwNP.",[310,359,360],"Biological Therapy","Biomarkers","2025-02-05",{"date":363,"type":31},"2025-02-06",{"date":365,"type":20},"2025-02-01",{"date":367,"type":20},"2026-07-01",{"name":124,"class":125},{"id":370,"slug":371,"hasResults":11,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":375,"eligibilityCriteria":376,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":377,"targetDuration":379,"studyType":51,"phases":4,"briefSummary":380,"conditions":381,"keywords":383,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":398},"100568594","real-life-evaluation-of-the-efficacy-of-biologicals-in-chronic-rhinosinusitis-with-nasal-polyposis-crswnp-100568594","NCT06683261","Real-life Evaluation of the Efficacy of Biologicals in Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)","Real-life Evaluation of the Efficacy of Biologicals in CRSwNP","RELIBIO","Inclusion Criteria:\n\n1. Participant must be at least 18 years of age at the time of signing the informed consent.\n2. Capable of giving signed informed consent.\n3. Participants should have CRSwNP.\n4. Participants should fulfil the reimbursement criteria for their prescribed biological (omalizumab, mepolizumab and\u002For dupilumab).\n\nExclusion Criteria:\n\n1\\. Patients treated with other biological therapies in the 3 months prior to the current biological (this is not applicable to patients who are in the trial and switch biological).",{"count":378,"type":20},300,"3 Years","The goal of this observational study is to learn more about the real-world efficacy of biologics in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP). All patients who are 18 years or older, who have CRSwNP and are eligible for reimbursement of a biological for the indication of CRSwNP can be included.\n\nThe main question is the efficacy of biologics in real life after 24 weeks. The main focus are patient reported outcomes measured via several questionnaires and the nasal polyp score, scored with nasal endoscopy.",[26,382],"Chronic Rhinosinusitis (CRS)",[384,81,385,386,387,388],"biologicals","real-world data study","mepolizumab","omalizumab","dupilumab","2024-11-07",{"date":391,"type":31},"2024-11-12",{"date":393,"type":31},"2022-09-23",{"date":395,"type":20},"2026-12",{"name":397,"class":125},"Universitaire Ziekenhuizen KU Leuven",8,{"id":400,"slug":401,"hasResults":11,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":4,"eligibilityCriteria":405,"healthyVolunteers":134,"sex":16,"minAge":47,"maxAge":406,"enrollmentInfo":407,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":409,"conditions":410,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":4},"100533836","correlation-between-the-microbiome-and-type-2-inflammatory-diseases-of-crswnp-100533836","NCT06231004","Correlation Between the Microbiome and Type 2 Inflammatory Diseases of CRSwNP","A Study on the Correlation Between the Microbiome and Type 2 Inflammatory Diseases of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)","Inclusion Criteria:\n\n\\- The diagnosis of CRSwNP was based on EPOS20201 ECRSwNP was defined as EO accounting for more than 27% of the total infiltration Subjects undergoing septoplasty due to anatomical variations served as controls Discontinuation of steroid (oral or aerosol) and antileukotriene therapy for at least 4 weeks prior to biopsy or surgery\n\nExclusion Criteria:\n\n\\- Exclude patients with a diagnosis of posterior maxillary sinus polyps, cystic fibrosis, allergic fungal sinusitis, primary ciliary dyskinesia, allergic rhinitis, immune deficiency, or coagulopathy Exclusion of patients with aspirin intolerance (AERD) Exclude smokers Exclude pregnant women\n\nHealthy Volunteers:\n\nOnly patients with deviated septum without any other nasal diseases served as a control group, and the participants in this group were not treated with corticosteroids and went in for septal correction. The rest of the criteria were the same","80 Years",{"count":408,"type":20},1000,"Nasal microorganisms, exfoliated cells, nasal secretions, fetal microorganisms and blood were collected from patients with chronic sinusitis with nasal polyps before medication. Nasal polyp tissues of the patients were clamped for pathologic biopsy in the outpatient clinic. Methylprednisolone was then administered to the patients for 17 days, and the nasal microbial changes were observed after the administration of the drug. Patients underwent surgical treatment after the administration of the drug, and postoperative patients were followed up for a long period of time until polyp recurrence. During the follow-up, the microorganisms in the patients' postoperative nasal cavities were collected and the postoperative microbial changes were recorded",[26],"2024-01-21",{"date":413,"type":31},"2024-01-30",{"date":415,"type":20},"2024-01-22",{"date":417,"type":20},"2032-09-01",{"name":419,"class":125},"The First Affiliated Hospital with Nanjing Medical University"]